Date: April 12, 2023
Time: 12:00 -1:30 PM EST
Overview:
Prostate cancer accounts for 27% of all cancer diagnoses for men and the second-highest rate of cancer-related deaths behind lung cancer. Survival rates have increased with improvements in early detection; however, unmet clinical needs remain for the management of castrate-sensitive prostate cancer (CSPC) and castrate-resistant prostate cancer (CRPC). Dysregulation of the cyclin-dependent kinase (CDK) pathway can lead to tumorigenesis in prostate cancer cells, and CDK4/6 inhibitors have been shown to disrupt androgen receptor signaling in tumors resistant to antiandrogens.
This live webcast will highlight the rationale and role of CDK4/6 inhibitors in the treatment of CSPC and CRPC. In this educational program, expert faculty will discuss unmet clinical needs in CSPC and CRPC, mechanisms of action of CDK4/6 inhibitors, and recent clinical trial data with these agents to inform physicians on practice-changing evidence to optimize care and survival outcomes for their patients.
Target audience:
This educational program is directed toward medical oncologists, urologists, and other allied health care professionals interested in the treatment of prostate cancer.
Learning objectives:
- Explain the pathophysiological mechanisms of CDK4/6 dysregulation in prostate cancer and rationale underlying their inhibition in advanced CSPC and CRPC
- Assess study design and clinical updates on CDK4/6 inhibitors investigated for the treatment of patients with advanced CSPC and CRPC
- Evaluate evidence from pivotal trials on CDK4/6 inhibitors within the context of evolving therapeutic strategies for patients with advanced prostate cancer
- Develop proactive strategies to monitor and mitigate adverse events associated with CDK4/6 inhibitors evaluated in patients with prostate cancer
Matthew R. Smith, MD, PhD
Claire and John Bertucci Endowed Chair in Genitourinary Cancers
Professor of Medicine, Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, MA
Rahul Aggarwal, MD
Associate Professor of Medicine
Associate Director for Clinical Research
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Tian Zhang, MD, MHS
Associate Professor of Internal Medicine
Harold C. Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
Dallas, TX
| Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings | ||
| Wednesday, April 12, 2023 | ||
| 12:00 PM to 1:30 PM ET | ||
| Live webcast | ||
| Time | ||
| 12:00 PM | Welcome and Introductions | Matthew R. Smith, MD, PhD |
| 12:10 PM | Overview of Metastatic CSPC and CRPC Treatment Landscape and Unmet Clinical Needs | Tian Zhang, MD, MHS |
| 12:30 PM | CDK4/6 Inhibition in Prostate Cancer: Rationale, Ongoing Trials, and Clinical Updates | Rahul Aggarwal, MD |
| 12:55 PM | Role of CDK4/6 Inhibitors in CSPC and CRPC Treatment: Panel Discussion | Moderator: |
| Matthew R. Smith, MD, PhD | ||
| Panelists: | ||
| Rahul Aggarwal, MD | ||
| Tian Zhang, MD, MHS | ||
| 1:15 PM | Audience Q&A | Matthew R. Smith, MD, PhD |
| 1:25 PM | Summary and Conclusions | Matthew R. Smith, MD, PhD |
| 1:30 PM | Adjourn | |
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.